Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Animals
Ankyrin Repeat
/ genetics
Cell Line, Tumor
Female
Humans
Iodine Radioisotopes
/ administration & dosage
Isotope Labeling
/ methods
Mice
Mice, Inbred BALB C
Mice, Nude
Molecular Imaging
/ methods
Neoplasms
/ diagnostic imaging
Protein Engineering
Radionuclide Imaging
/ methods
Receptor, ErbB-2
/ metabolism
Recombinant Proteins
/ administration & dosage
Tissue Distribution
Xenograft Model Antitumor Assays
DARPin
HER2
imaging
radionuclide
iodine
radioiodination
Journal
International journal of oncology
ISSN: 1791-2423
Titre abrégé: Int J Oncol
Pays: Greece
ID NLM: 9306042
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
27
09
2018
accepted:
25
01
2019
pubmed:
11
4
2019
medline:
27
8
2019
entrez:
11
4
2019
Statut:
ppublish
Résumé
Evaluation of human epidermal growth factor receptor 2 (HER2) expression levels in breast and gastroesophageal cancer is used for the stratification of patients for HER2‑targeting therapies. The use of radionuclide molecular imaging may facilitate such evaluation in a non‑invasive way. Designed ankyrin repeat proteins (DARPins) are engineered scaffold proteins with high potential as probes for radionuclide molecular imaging. DARPin G3 binds with high affinity to HER2 and may be used to visualize this important therapeutic target. Studies on other engineered scaffold proteins have demonstrated that selection of the optimal labeling approach improves the sensitivity and specificity of radionuclide imaging. The present study compared two methods of labeling G3, direct and indirect radioiodination, to select an approach providing the best imaging contrast. G3‑H6 was labeled with iodine‑124, iodine‑125 and iodine‑131 using a direct method. A novel construct bearing a C‑terminal cysteine, G3‑GGGC, was site‑specifically labeled using [125I]I‑iodo‑[(4‑hydroxyphenyl)ethyl]maleimide (HPEM). The two radiolabeled G3 variants preserved binding specificity and high affinity to HER2‑expressing cells. The specificity of tumor targeting in vivo was demonstrated. Biodistribution comparison of [131I]I‑G3‑H6 and [125I]I‑HPEM‑G3‑GGGC in mice, bearing HER2‑expressing SKOV3 xenografts, demonstrated an appreciable contribution of hepatobiliary excretion to the clearance of [125I]I‑HPEM‑G3‑GGGC and a decreased tumor uptake compared to [131I]I‑G3‑H6. The direct label provided higher tumor‑to‑blood and tumor‑to‑organ ratios compared with the indirect label at 4 h post‑injection. The feasibility of high contrast PET/CT imaging of HER2 expression in SKOV3 xenografts in mice using [124I]I‑G3‑H6 was demonstrated. In conclusion, direct radioiodination is the preferable approach for labeling DARPin G3 with iodine‑123 and iodine‑124 for clinical single photon emission computed tomography and positron emission tomography imaging.
Identifiants
pubmed: 30968147
doi: 10.3892/ijo.2019.4712
pmc: PMC6411343
doi:
Substances chimiques
Iodine Radioisotopes
0
Recombinant Proteins
0
ERBB2 protein, human
EC 2.7.10.1
Receptor, ErbB-2
EC 2.7.10.1
Types de publication
Comparative Study
Journal Article
Langues
eng
Pagination
1209-1220Références
Cancer Res. 1990 Feb 1;50(3 Suppl):857s-861s
pubmed: 2297734
Cancer Res. 2015 Oct 15;75(20):4364-71
pubmed: 26297736
J Clin Oncol. 2013 Nov 1;31(31):3997-4013
pubmed: 24101045
Exp Ther Med. 2011 May;2(3):523-528
pubmed: 22977535
Lancet Oncol. 2014 Sep;15(10):1137-46
pubmed: 25130998
Cancer Res. 2010 Feb 15;70(4):1595-605
pubmed: 20124480
J Nucl Med. 2018 Jan;59(1):93-99
pubmed: 28864631
Lancet Oncol. 2012 Jan;13(1):25-32
pubmed: 22153890
Gastric Cancer. 2015 Jul;18(3):476-84
pubmed: 25038874
Radiology. 2012 Apr;263(1):179-88
pubmed: 22344401
J Struct Funct Genomics. 2004;5(1-2):75-86
pubmed: 15263846
J Nucl Med. 2018 Jun;59(6):885-891
pubmed: 29545374
Eur J Med Chem. 2014 Nov 24;87:519-28
pubmed: 25282673
Cancer Biother Radiopharm. 2005 Jun;20(3):239-48
pubmed: 15989469
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Eur J Nucl Med Mol Imaging. 2007 May;34(5):722-733
pubmed: 17146656
J Nucl Med. 2012 Jun;53(6):953-60
pubmed: 22586147
Science. 1987 Jan 9;235(4785):177-82
pubmed: 3798106
Int J Rad Appl Instrum A. 1987;38(12):1051-5
pubmed: 2828275
J Nucl Med. 2011 Mar;52(3):461-9
pubmed: 21321280
Bioconjug Chem. 2005 Nov-Dec;16(6):1547-55
pubmed: 16287254
Breast Cancer Res Treat. 2011 Oct;129(3):659-74
pubmed: 21698410
Breast Cancer Res Treat. 2011 Jan;125(2):553-61
pubmed: 20628810
J Nucl Med. 2015 Jun;56(6):939-44
pubmed: 25908832
J Clin Oncol. 2014 Jul 1;32(19):2078-99
pubmed: 24799465
Endocrinology. 1959 Jan;64(1):103-9
pubmed: 13619565
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):288-301
pubmed: 25391547
Methods Mol Biol. 2014;1060:309-30
pubmed: 24037848
Nat Protoc. 2007;2(4):924-32
pubmed: 17446874
PLoS One. 2011;6(9):e24739
pubmed: 21931838
Ann Oncol. 2012 Sep;23 Suppl 10:x349-53
pubmed: 22987990
Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):81-93
pubmed: 18712381
Cancer Res. 2006 Apr 15;66(8):4339-48
pubmed: 16618759
Nucl Med Rev Cent East Eur. 2012 Aug 28;15(2):120-3
pubmed: 22936505
J Mol Biol. 2003 Sep 12;332(2):489-503
pubmed: 12948497
J Nucl Med. 2014 Apr;55(4):665-71
pubmed: 24614223
Contrast Media Mol Imaging. 2018 Jun 6;2018:6930425
pubmed: 29977173
Theranostics. 2016 Jan 01;6(2):262-71
pubmed: 26877784
Protein Expr Purif. 2005 May;41(1):207-34
pubmed: 15915565
J Nucl Med. 1994 May;35(5):899-908
pubmed: 8176479